December 2007
Worldwide Biotech;Dec2007, Vol. 19 Issue 12, p3
Trade Publication
The article reports on the positive interim results announced by BioLineRx Ltd. of an ongoing Phase 2 trial of BL-1020, a gamma-aminobutyric acid (GABA) enhanced antipsychotic. Morris C. Laster, MD, CEO of BioLineRx, said that these results from severely ill treatment resistant patients with psychosis are extremely encouraging, as they further substantiate existing preclinical and clinical data suggesting that BL-1020 possesses the efficacy of currently available antipsychotics but without their compliance limiting motor or metabolic side effects.


Related Articles

  • BioLineRx's antipsychotic drug found effective in Phase IIa trial.  // PharmaWatch: CNS;Mar2008, Vol. 7 Issue 3, p11 

    The article reports on the positive results shown in a Phase IIa trial of BioLineRX Ltd.'s BL-1020, a gamma-aminobutyric acid-enhanced antipsychotic. It showed statistically significant efficacy with no significant change in weight and no increase in extrapyramidal symptoms at study completion....

  • EPS similar for first- and secondlikely generation antipsychotics.  // Reactions Weekly;4/21/2012, Issue 1398, p4 

    The article reports on a secondary analysis of a pragmatic randomised clinical trial which shows no significant difference in the incidence of extrapyramidal side effects (EPS) between first- and second-generation antipsychotic drugs.

  • BioLineRx to Present Data from the Successfully Completed Phase IIb Trial of BL-1020 at European Conference on Schizophrenia Research.  // Biomedical Market Newsletter;9/30/2011, Vol. 21, p497 

    The article reports on the announcement of BioLineRx Ltd. on the release of data from the completed phase IIb trial of GABA-enhanced antipsychotic BL-1020 to be presented at the3rd European Conference on Schizophrenia Research (ECSR) held in Berlin, Germany. The trial has demonstrated the...

  • BioLineRx reports new results from study of antipsychotic drug.  // PharmaWatch: CNS;Aug2009, Vol. 8 Issue 8, p11 

    The article reports on the study unveiled by BioLineRx Ltd., a drug development company, about its GABA enhanced BL-1020 drug's mode of action. The study found that BL-1020, an orally antipsychotic drug, is effective in treating patients with schizophrenia. It also revealed that the drug can...

  • Aripiprazole.  // Reactions Weekly;7/26/2008, Issue 1212, p9 

    A case study involving three men with bipolar disorder or schizophrenia who developed reversible hypertriglyceridaemia while receiving aripiprazole during an open-label outpatient clinical trial is presented. The clinical history of the patients, the laboratory examinations performed on the...

  • Strategies for optimizing functionality in patients with psychotic disorders: An evidence-based approach.  // American Journal of Health-System Pharmacy;1/15/2007 Supplement, Vol. 64, pS2 

    Information about several papers discussed at a symposium on the strategies to optimize the functionality of patients with psychotic disorders is presented. The Clinical Antipsychotic Trial of International Effectiveness-Alzheimer's Disease has given its support to the efficacy of some...

  • Continuing Education.  // American Journal of Health-System Pharmacy;1/15/2007 Supplement, Vol. 64, pS24 

    The article focuses on the strategies to optimize the functionality of patients with psychotic disorders. The author cited some learning objectives in this article including the identification of problems in Medicare Part D for elderly patients, the challenges faced by pharmacists with the said...

  • Managing the metabolic adverse effects of antipsychotic drugs in patients with psychosis. Lambert, Tim // Australian Prescriber;Aug2011, Vol. 34 Issue 4, p97 

    Antipsychotic medications are widely prescribed and carry a variable propensity to cause weight gain and its attendant sequelae - hyperglycaemia, hypertension and hyperlipidaemia. These metabolic risks, along with smoking and poor lifestyle habits, occur between two and five times more often in...

  • History of alcohol abuse reduces response to antipsychotics in people with first episode psychosis. Green, A. I.; Tohen, M. F.; Hamer, R. M. // Evidence Based Mental Health;Aug2004, Vol. 7 Issue 3, p87 

    The article focuses on the prevalence of substance use disorder (SUD) among people with first episode psychosis, and their response to antipsychotic drugs. A randomized controlled trial was conducted and 262 people aged 16-40 years, with schizophrenia, schizophreniform and schizoaffective...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics